Meeting
2022 ASCO Annual Meeting
VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: Meta-analysis and systematic review.
Authors
Ines Esteves Domingues Pires Da Silva
Melanoma Institute Australia, The University of Sydney, Sydney, Australia
Ines Esteves Domingues Pires Da Silva , Serigne N. Lo , Jordan W. Conway , Richard A. Scolyer , Matteo S. Carlino , Alexander M. Menzies , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Cancer Angiogenesis and Metastases
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3024)
DOI
10.1200/JCO.2022.40.16_suppl.3024
Abstract #
3024
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Effect of subsequent chemotherapy on overall survival in first-line chemotherapy with targeted agents for patients with metastatic colorectal cancer: Systematic review and meta-analysis of randomized control trials.
First Author: Daisuke Sakai
Poster
2024 ASCO Genitourinary Cancers Symposium
A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.
First Author: Angus Hall
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2022 ASCO Annual Meeting
Brain metastases in the setting of stable extracranial disease: A systematic review and meta-analysis.
First Author: Alyssa Y. Li